Celebrating our 10th anniversary – Unlock our special offer today

Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Europe Packaging and Packaging Waste Directive revision proposal approved ...
  • Europe EU proposal for directive on corporate sustainability due diligence ...
  • Europe European Parliament adopts proposal about right to repair of goods ...
  • Germany BGH sets limit for 'small amount' of cannabis ...
  • United States CPC’s new legislative agenda prioritises cannabis legalisation ...
  • Lithuania Proposed changes to fibre hemp regulation to go to Seimas this week ...
  • Turkey Ministry urged to legalise hemp cultivation in Karaman province ...
  • Missouri - United States Attorney general issues CIDs over illegal marketing practices ...
  • Minnesota - United States Cannabis and hemp bill passes House and heads to Senate ...
  • Germany Government wants to tighten rules around new cannabis law ...
  • Israel Procedure to acquire medical cannabis export licence updated ...
  • France Bill introduced to try legalising recreational cannabis based on German model ...
View all
News analysis

Cannabis & Me – critics fear bias before major psychiatric study gets under way

Written by || 20th October 2022 || News analysis | Cannabis – medical | Cannabis – recreational | Health and science | GeographiesEurope United Kingdom

A major new study into the impact of cannabis on the brain has attracted controversy and brought accusations of bias from within the industry before it even begins.

Headed by Marta Di Forti, senior clinical fellow at King’s Institute of Psychiatry, Psychology and Neuroscience, and funded by the UK Medical Research Council, Cannabis & Me will use DNA genetic and epigenetics testing, psychological and cognitive analysis, and virtual reality to explore the link between a user’s biological make-up and the effect cannabis has on an estimated 6,000 participants. But some experts have raised concerns that the results could be biased towards suggesting the potentially harmful effects of cannabis.

Read full article

Download the full news analysis

“Cannabis & Me – critics fear bias before major psychiatric study gets under way”








    I'm already a subscriber

    Login

    Author default picture

    Lorraine Mullaney

    Senior writer
    Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.